Atico Reports Multiple High-Grade Intercepts up to 8.70m of 11.44% Cu, 14.65 g/t Au and 6.16m of 13.32% Cu, 2.79 g/t Au and Continues to Extend the Ore Body at El Roble Mine in Colombia

(TSX-V:ATY),(OTC US:ATCMF),(Other OTC:ATCMF), VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) — Atico Mining Corporation (TSX.V: ATY | OTCQX: ATCMF) (“Atico” or the “Company”) is pleased to announce positive results for 19 drill holes completed during 2025 in an area of historical mining to expand tonnage at the El Roble mine. In addition, the Company […]

Former NFL Player Nick Ferguson Speaks Out on Mental Health on Fox 11

LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) — Former NFL safety Nick Ferguson appeared on Fox 11 News Friday, sharing his mental health journey in professional football ahead of the Rams Mental Health Awareness Game against the Buccaneers. The interview follows the recent suicide of Dallas Cowboys defensive end Marshawn Kneeland, which has intensified the

Condor’s First Horizontal Well in Uzbekistan Reaches TD While Two New Zone Workovers in an Adjacent Field Increase Daily Production to Approximately 12,000 boepd

(TSX:CDR), CALGARY, Alberta, Nov. 24, 2025 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based, internationally focused energy transition company working in Central Asia is pleased to announce its first horizontal well in the Andakli field in Uzbekistan, Andakli-23 (“A-23”) has reached total depth (“TD”) in the Jurassic carbonate reservoir

SunPower Closes $37.5M Ambia Solar Acquisition

(NasdaqGM:CSLR),(NasdaqGM:SPWR),(NASDAQ:SPWRW), OREM, Utah, Nov. 24, 2025 (GLOBE NEWSWIRE) — SunPower Inc. (herein “SunPower,” the “Company,” or Nasdaq: “SPWR”) a solar technology, services, and installation company, today announced that it has closed its $37.5 million strategic acquisition of Ambia Solar (“Ambia”) to create the No. 5 U.S. residential solar company, based on Ohm Analytics rankings. SunPower

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

(NASDAQ:CMMB), TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at

This Thanksgiving, Experts Want Parents to Know That Picky Eating Isn’t Always “Just Picky Eating”

Indianapolis, Nov. 24, 2025 (GLOBE NEWSWIRE) — Thanksgiving is all about family, food and togetherness, but for many children, especially those with autism spectrum disorder (ASD) or sensory differences, the holiday table can feel more overwhelming than enjoyable. While picky eating is common, Hopebridge Autism Therapy Centers wants to remind families that some children are

Xcel Brands Partners with At Home with Shannon to Launch a New Era of Inspired Living Through Longaberger

(NASDAQ:XELB), NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Xcel Brands, Inc. (NASDAQ: XELB), an industry-leading media and consumer products company specializing in building influencer-driven brands through social commerce and livestreaming, is proud to announce a new partnership between Longaberger and Shannon Doherty, creator of At Home with Shannon. Together, they will introduce a new

LifeMD Recognized by the 2025 Deloitte Technology Fast 500(TM) and by TIME’s America’s Growth Leaders of 2026

(NasdaqGM:LFMD),(NasdaqGM:LFMDP), NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500(TM) and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue

Day One Announces Three Year Follow-Up Data From OJEMDA(TM) (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting

(NASDAQ:DAWN), Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at least 12 months The median time to next treatment (TTNT) following initiation of OJEMDA exceeded 3.5 years   BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) —

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

(NASDAQ:AKBA), CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) — Akebia Therapeutics(R), Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that members of its executive team will participate in a Fireside Chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December

Scroll to Top